Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
申请人:Allergan, Inc.
公开号:US08338415B2
公开(公告)日:2012-12-25
The present invention relates to a compound of Formula I:
or a pharmaceutically acceptable salt thereof, as disclosed herein. The present invention also relates to pharmaceutical compositions comprising said compounds and to methods of using said compounds and compositions for modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-ones and derivatives thereof as kinase inhibitors
申请人:Allergan, Inc.
公开号:US08877923B2
公开(公告)日:2014-11-04
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONES AND DERIVATIVES THEREOF AS KINASE INHIBITORS
申请人:Allergan, Inc.
公开号:US20130123259A1
公开(公告)日:2013-05-16
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Regioselective Pd-catalyzed alkylative lactonizations of 4-hydroxy-2-alkynecarboxylates with organoboronic acids
作者:Chang Ho Oh、Su Jin Park、Jin Hyang Ryu、Arun Kumar Gupta
DOI:10.1016/j.tetlet.2004.07.129
日期:2004.9
The palladium-catalyzed addition of aryl- and alkenylboronic acids to 4-hydroxy-2-alkynecarboxylates and in situ lactonization would constitute a novel methodology for the synthesis of various butenolides with an excellent stereoselectivity and a high control of regioselectivity. (C) 2004 Published by Elsevier Ltd.